Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
45 hedge funds and large institutions have $65.5M invested in Agile Therapeutics in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 13 closing their positions.
1,700% more call options, than puts
Call options by funds: $288K | Put options by funds: $16K
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less funds holding
Funds holding: 47 → 45 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
41% less capital invested
Capital invested by funds: $111M → $65.5M (-$45.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$15.7M |
| 2 |
BC
Broadfin Capital
New York
|
+$1.67M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
| 4 |
Renaissance Technologies
New York
|
+$1.29M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$820K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.58M |
| 2 |
DM
Deerfield Management
New York
|
-$5.45M |
| 3 |
RA
Royce & Associates
New York
|
-$2.99M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.44M |
| 5 |
AC
Aisling Capital
New York
|
-$2.33M |
AGRX Hedge Fund Activity: Q4 2017 in Review
45 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2017, worth a combined $65.5M — down 41% from $111M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of AGRX and 11 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 16 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $15.7M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $5.58M sold.
- 45 institutional investors held Agile Therapeutics (AGRX) as of Q4 2017, down from 47 in Q3 2017.
- Funds reported $65.5M of Agile Therapeutics stock for Q4 2017, down 41% quarter-over-quarter.
- 11 funds opened new Agile Therapeutics positions in Q4 2017 and 13 closed out, a net change of -2 holders.
- The largest Agile Therapeutics buyer in Q4 2017 was Perceptive Advisors, an estimated $15.7M added.
- The largest Agile Therapeutics seller in Q4 2017 was Cormorant Asset Management, an estimated $5.58M sold.
Based on aggregated 13F filings for Q4 2017.